NUVISAN

DISCOVERY

Drug Discovery Screening Solutions

Screening Solutions for your Drug Development

From Hit Discovery to Lead Optimization

After identifying and validating your drug target, High-Throughput Screening (HTS) is conducted to identify hit compounds.

We have strong expertise in developing the optimal assay for your target, using biochemical and cell-based approaches. To perform our screening campaigns in High-Throughput (1536 well plate format), we provide access with flexible options to a high-quality and industry-leading compound library with >3 million compounds. NUVISAN ICB can also rely on pharma-proven in-house protein production and structural biology support to be able to meet your needs.

To make sure the most promising hit compounds are extracted, your hits are profiled in custom made assays and qualified using additional data mining from our Life Science Data Base (LSDB) of >300 million data sets. Compounds are further developed in Hit-to-Lead (H2L) programs, using our cutting-edge capabilities in Computational Chemistry and Medicinal Chemistry. Leads are then investigated in Lead Optimization (LO) programs until the preclinical candidate compound is identified. We closely collaborate with computational compound design, therapeutic research and preclinical compound profiling functions to provide a comprehensive set of in vitro/in vivo pharmacology and DMPK assays in order to optimize on-target activity, to minimize off-target effects, and to rule out sources of toxicity.

At every stage of your drug discovery project, robust and reproducible assays are the key to success. Our 70 PhD level scientists and skillful laboratory professionals have accumulated decades of experience in developing the right assays for your target. Biochemical, biophysical, cell-based and phenotypic endpoints support lead identification and lead optimization with a broad technology and target biology base.

Our team at NUVISAN ICB has originated from the Bayer Pharma R&D site in Berlin (Germany). With its unique know-how and state-of-the-art equipment we offer not only stand-alone target identification/validation, screening and lead optimization services, but also fully integrated packages along all the phases of the drug discovery process.

Our screening solutions at a glance

More than 20 years of experience in designing and conducting screening campaigns

Integrated screening and medicinal chemistry services for highest quality and efficiency

An industry-leading library of >3 million compounds for HTS and follow-up testing built on Bayer's and Schering's legacy data

Best-in-class assay capabilities and high-throughput equipment for biochemical, cell-based and High-Content assays



SCREENING SOLUTIONS AT **NUVISAN**

Accelerate your time to the clinic by relying on our drug discovery services - from target identification and high-throughput compound library screening to lead optimization and preclinical development - managed by one project team gathered under one roof.

Our extensive assay and screening expertise covers a wide array of compound target classes including ion channels, GPCRs, kinases, metabolic enzymes, antibodies, protein-protein interactions, proteases, nuclear receptors, phosphodiesterases (PDE), phosphatases, ubiquitin and phenotypic assays etc… Moreover, our computational and medicinal chemistry expertise includes programs for small molecules (SMOLs) and for degraders (PROTACs) alike.

OUR BROAD RANGE OF SCREENING ASSAYS INCLUDE:

- Cell-based assays (reporter assays, TR-FRET, NanoBiT, NanoBRET, etc.)
- Binding, enzyme activity and protein-protein interaction assays
- High-Content Assays (HCA)
- Thermal shift assay (TSA)
- Mass spectrometric-based biochemical assays



With us,

advance your discovery research across a range of therapeutic areas including oncology, immunology, women's health, urology, dermatology, gastrointestinal diseases, rheumatoid diseases, and more.



Highlights

Decades of successful pharma screening track record

High-Throughput Screening infrastructure using an industry-leading compound library

Fully automated High-Content Screening setups for large scale screening campaigns, and multi-parameter analyses in 2D & 3D and 4D

Specialty HTS with MALDI-TOF and radioactive assays in 1536 well format



STATE-OF-THE-ART SCREENING EQUIPMENT AT NUVISAN ICB

- Fully automated Labcyte Echo Liquid Handler systems
- Fully automated HTS system
- BenchCel Microplate Handler Workstations
- BMG Labtech PHERAstar reader
- ViewLux™ ultra HTS Microplate Imager
- HCA Reader (Opera, Phenix and ImageXpress)
- FLIPR Tetra
- Centrifugal Blue®Washer
- CyBi-Well systems
- Bruker rapifleX MALDI PharmaPulse MS spectrometer
- Rapidfire MS system ESI
- Intellicyt iQue3 HT Flow Cytometer
- TSA readers
- BIAcore systems

NUVISAN

YOUR SCIENTIFIC CRO PARTNER

NUVISAN is a fully integrated CRO/CDMO offering all solutions from drug discovery to Proof of Concept in patients including: target identification, high throughput screening, compound profiling, pre-clinical DMPK, toxicology, API synthesis, formulation development, pharmaceutical analysis, and clinical trials in healthy volunteers and patient populations.

With capabilities distributed over 5 locations in Europe and with more than 40 years of experience, we deliver high-quality solutions certified by various accreditations and inspections (e.g. BfArM, EMA, FDA, ANVISA, ANSES, AAALAC, GLP, GMP).

40 **A trusted scientific partner**
With a 40-year track record of customer satisfaction

A wide range of expertise
A unique, comprehensive and integrated offer from target identification to clinical trials

A data-focused expert
Our top priority is to ensure accurate, reliable, and consistent data quality

A flexible service provider
Fast turnaround ability and strong responsiveness to change

Enquire now

Whether you need support in specific areas only, or need a more comprehensive offer, NUVISAN can tailor a solution to fit your specific requirements.

Any questions or need further information?

Call: +49 731 9840-0
Mail: hello@nuvisan.com
Web: www.nuvisan.com

Follow NUVISAN on Linkedin

NUVISAN GmbH | Wegenerstrasse 13 | 89231 Neu-Ulm | Germany